OBI Pharma Inc (4174):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:OBI Pharma Inc (4174) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8254
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:台湾
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
OBI Pharma Inc (OBI Pharma) is a biopharmaceutical company that develops therapies for the treatment of cancer and infectious diseases. The company’s products include adagloxad simolenin, an active immunotherapy which is intended for the treatment of metastatic breast cancer; and OBI-833, a cancer vaccine for epithelial cancers other than breast and ovarian cancer. It also develops active immunotherapies intended for the treatment of various lung, prostate, pancreatic, stomach and ovarian cancers. OBI Pharma develops its pipeline products through its carbohydrate synthesis discovery platform. The company has collaboration with research institutes including cancer centers to enhance its pipeline products. It operates in the US, Taiwan and China. OBI Pharma is headquartered in Taipei, Taiwan.

OBI Pharma Inc (4174) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OBI Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
OBI Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 9
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
OBI Pharma to Acquire TH-3424 from Threshold Pharma 11
Venture Financing 12
Optimer Biotech Raises US$18.3 Million In Financing 12
Partnerships 13
Merck Enters into Agreement with OBI Pharma 13
Licensing Agreements 14
OBI Pharma Enters into Licensing Agreement with Abzena 14
Equity Offering 15
OBI Pharma Raises USD51 Million through Issue of Shares 15
Acquisition 16
OBI Pharma to Acquire 70% Stake in AP Biosciences from AbProtix 16
Taiwanese Investor Consortium Completes First Tranche Acquisition Of Remaining 43.5% Stake In Optimer Biotech 17
Optimer Pharma Acquires 0.7% Stake In Optimer Biotech For US$0.5 Million 19
Optimer Pharma Sells Minority Stake In Optimer Biotech 20
OBI Pharma Inc – Key Employees 22
OBI Pharma Inc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Product News 24
01/17/2018: OBI Pharma Announces FDA Clearance Of IND Application For A Phase 1 Study Of A Monoclonal Antibody Cancer Immunotherapy (OBI-888) 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
OBI Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OBI Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OBI Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 8
OBI Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 9
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
OBI Pharma to Acquire TH-3424 from Threshold Pharma 11
Optimer Biotech Raises US$18.3 Million In Financing 12
Merck Enters into Agreement with OBI Pharma 13
OBI Pharma Enters into Licensing Agreement with Abzena 14
OBI Pharma Raises USD51 Million through Issue of Shares 15
OBI Pharma to Acquire 70% Stake in AP Biosciences from AbProtix 16
Taiwanese Investor Consortium Completes First Tranche Acquisition Of Remaining 43.5% Stake In Optimer Biotech 17
Optimer Pharma Acquires 0.7% Stake In Optimer Biotech For US$0.5 Million 19
Optimer Pharma Sells Minority Stake In Optimer Biotech 20
OBI Pharma Inc, Key Competitors 21
OBI Pharma Inc, Key Employees 22
OBI Pharma Inc, Other Locations 23
OBI Pharma Inc, Subsidiaries 23

List of Figures
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
OBI Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[OBI Pharma Inc (4174):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Santos Ltd (STO):企業の財務・戦略的SWOT分析
    Santos Ltd (STO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Arab African International Bank:企業の戦略・SWOT・財務情報
    Arab African International Bank - Strategy, SWOT and Corporate Finance Report Summary Arab African International Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Compania Minera Antamina SA:企業の戦略・SWOT・財務情報
    Compania Minera Antamina SA - Strategy, SWOT and Corporate Finance Report Summary Compania Minera Antamina SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • United BioSource Corp-製薬・医療分野:企業M&A・提携分析
    Summary United BioSource Corp (UBC), a subsidiary of Express Scripts Holding Company is a provider of pharmaceutical support services. The company offers medicines and medical products. Its services comprise clinical development and late stage research, risk management and pharmacovigilance, nursing …
  • Canbriam Energy Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Canbriam Energy Inc (Canbriam) is an oil and gas exploration company that offers finding and developing liquids rich natural gas resources. The company develops liquids rich natural gas resources in the Western Canadian Sedimentary Basin. It owns and operates oil and gas producing properties …
  • H.B. Fuller Co (FUL):企業の財務・戦略的SWOT分析
    H.B. Fuller Co (FUL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Sinphar Pharmaceutical Co Ltd (1734):企業の財務・戦略的SWOT分析
    Sinphar Pharmaceutical Co Ltd (1734) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Veracyte Inc (VCYT):企業の財務・戦略的SWOT分析
    Summary Veracyte Inc (Veracyte) is a molecular diagnostics company that uses genomic technology to resolve diagnostic ambiguity. The company’s pipeline products include Afirma thyroid FNA analysis for the diagnosis of thyroid cancer based on its proprietary afirma gene expression classifier. It also …
  • Supernus Pharmaceuticals Inc (SUPN):企業の財務・戦略的SWOT分析
    Supernus Pharmaceuticals Inc (SUPN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Formosa Laboratories Inc (4746):製薬・医療:M&Aディール及び事業提携情報
    Summary Formosa Laboratories Inc (Formosa Laboratories) is a producer of active pharmaceutical ingredients and UV-filters. The company’s active pharmaceutical ingredients include cholesterol and phosphate binders, anticancers, CNS agents, immunomodulators, MRI enhancing agents, anti-inflammatory and …
  • Sammons Enterprises Inc:企業の戦略・SWOT・財務情報
    Sammons Enterprises Inc - Strategy, SWOT and Corporate Finance Report Summary Sammons Enterprises Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Young’s Market Co LLC:企業の戦略的SWOT分析
    Young's Market Co LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Tullow Oil Plc (TLW):石油・ガス:M&Aディール及び事業提携情報
    Summary Tullow Oil Plc (Tullow) is an independent upstream oil and gas company. It explores for, develops and produces oil and natural gas in Africa and South America. The company has licenses, both onshore and offshore, across Africa, and offshore exploration licenses in Guyana, Suriname, Uruguay, …
  • ZyGEM NZ Ltd:医療機器:M&Aディール及び事業提携情報
    Summary ZyGEM NZ Ltd (ZyGEM), a subsidiary of MicroGEM International PLC is a drug development company that develops and technologies for life science, agricultural and horticultural industries. The company produces DNA extraction products, and enzymes used in diagnostics, molecular biology and indu …
  • Nautilus Minerals Inc.:企業のM&A・事業提携・投資動向
    Nautilus Minerals Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Nautilus Minerals Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Vitasoy International Holdings Ltd.:企業の戦略・SWOT・財務分析
    Vitasoy International Holdings Ltd. - Strategy, SWOT and Corporate Finance Report Summary Vitasoy International Holdings Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Bank Of Ningbo Co. Ltd.:企業の戦略・SWOT・財務分析
    Bank Of Ningbo Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Bank Of Ningbo Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Quest Diagnostics Incorporated:企業のM&A・事業提携・投資動向
    Quest Diagnostics Incorporated - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Quest Diagnostics Incorporated Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Electro Optic Systems Holdings Ltd (EOS):企業の財務・戦略的SWOT分析
    Electro Optic Systems Holdings Ltd (EOS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • CME Group Inc:企業のM&A・事業提携・投資動向
    CME Group Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CME Group Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆